文献速递预防保健、筛查与疫苗常见症状与未分化疾病

新冠疫苗接种、SARS-CoV-2感染与免疫介导神经系统事件风险的相关性

Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
PubMed 文献 · BMJ · 2022-03-16

结果显示疫苗接种后贝尔麻痹、脑脊髓炎、吉兰-巴雷综合征发生率与背景率一致,无安全信号;而SARS-CoV-2感染后上述事件发生率高于预期。

要点

  • 接种ChAdOx1 nCoV-19、BNT162b2、mRNA-1273或Ad.26.COV2.S后,贝尔麻痹、脑脊髓炎、吉兰-巴雷综合征发生率与背景率一致。
  • SARS-CoV-2感染后贝尔麻痹、脑脊髓炎、吉兰-巴雷综合征发生率高于预期。
  • 横贯性脊髓炎在所有疫苗队列中罕见(<5例事件),无法分析。

核心结论

  • 新冠疫苗接种与贝尔麻痹、脑脊髓炎、吉兰-巴雷综合征及横贯性脊髓炎之间未观察到安全信号。
  • SARS-CoV-2感染后贝尔麻痹、脑脊髓炎和吉兰-巴雷综合征风险增加。

研究设计与样本

  • 人群历史率比较研究与自控病例系列分析。
  • 数据来源为英国初级保健记录及西班牙初级保健记录链接医院数据。

主要发现

  • 疫苗接种后21天内贝尔麻痹、脑脊髓炎、吉兰-巴雷综合征发生率与背景率一致。
  • 仅对贝尔麻痹进行自控病例系列分析,未发现接种者安全信号。
  • 英国数据中SARS-CoV-2感染后贝尔麻痹标准化发病比为1.33(1.02至1.74)。
  • 英国数据中SARS-CoV-2感染后脑脊髓炎标准化发病比为6.89(3.82至12.44)。
  • 英国数据中SARS-CoV-2感染后吉兰-巴雷综合征标准化发病比为3.53(1.83至6.77)。

关键数值与推荐

  • 疫苗接种后21天内评估贝尔麻痹、脑脊髓炎、吉兰-巴雷综合征和横贯性脊髓炎发生率。
  • SARS-CoV-2阳性检测后90天内评估上述事件发生率。
  • 背景率取自2017至2019年一般人群队列。
  • 横贯性脊髓炎在所有疫苗队列中事件数<5例,无法分析。

临床怎么用

  • 全科医生可向患者说明新冠疫苗接种未显示与上述免疫介导神经系统事件相关的安全信号。
  • 对SARS-CoV-2感染者应关注贝尔麻痹、脑脊髓炎和吉兰-巴雷综合征的早期识别。

局限性

  • 自控病例系列分析仅对贝尔麻痹进行,因统计效力有限。
  • 横贯性脊髓炎事件数过少无法分析。
  • 数据截止时间英国为2021年5月9日、西班牙为2021年6月30日。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the association between covid-19 vaccines, SARS-CoV-2 infection, and risk of immune mediated neurological events. DESIGN: Population based historical rate comparison study and self-controlled case series analysis. SETTING: Primary care records from the United Kingdom, and primary care records from Spain linked to hospital data. PARTICIPANTS: 8 330 497 people who received at least one dose of covid-19 vaccines ChAdOx1 nCoV-19, BNT162b2, mRNA-1273, or Ad.26.COV2.S between the rollout of the vaccination campaigns and end of data availability (UK: 9 May 2021; Spain: 30 June 2021). The study sample also comprised a cohort of 735 870 unvaccinated individuals with a first positive reverse transcription polymerase chain reaction test result for SARS-CoV-2 from 1 September 2020, and 14 330 080 participants from the general population. MAIN OUTCOME MEASURES: Outcomes were incidence of Bell's palsy, encephalomyelitis, Guillain-Barré syndrome, and transverse myelitis. Incidence rates were estimated in the 21 days after the first vaccine dose, 90 days after a positive test result for SARS-CoV-2, and between 2017 and 2019 for background rates in the general population cohort. Indirectly standardised incidence ratios were estimated. Adjusted incidence rate ratios were estimated from the self-controlled case series. RESULTS: The study included 4 376 535 people who received ChAdOx1 nCoV-19, 3 588 318 who received BNT162b2, 244 913 who received mRNA-1273, and 120 731 who received Ad26.CoV.2; 735 870 people with SARS-CoV-2 infection; and 14 330 080 people from the general population. Overall, post-vaccine rates were consistent with expected (background) rates for Bell's palsy, encephalomyelitis, and Guillain-Barré syndrome. Self-controlled case series was conducted only for Bell's palsy, given limited statistical power, but with no safety signal seen for those vaccinated. Rates were, however, higher than expected after SARS-CoV-2 infection. For example, in the data from the UK, the standardised incidence ratio for Bell's palsy was 1.33 (1.02 to 1.74), for encephalomyelitis was 6.89 (3.82 to 12.44), and for Guillain-Barré syndrome was 3.53 (1.83 to 6.77). Transverse myelitis was rare (<5 events in all vaccinated cohorts) and could not be analysed. CONCLUSIONS: No safety signal was observed between covid-19 vaccines and the immune mediated neurological events of Bell's palsy, encephalomyelitis, Guillain-Barré syndrome, and transverse myelitis. An increased risk of Bell's palsy, encephalomyelitis, and Guillain-Barré syndrome was, however, observed for people with SARS-CoV-2 infection.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Li X, Raventós B, Roel E, et al. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. BMJ. 2022. PMID: 35296468. doi:10.1136/bmj-2021-068373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。